Last reviewed · How we verify
Infantile autism
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Risperdal · Johnson & Johnson (Janssen)
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder. - Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Risperdal · Ohio State University
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Infantile autism patent landscape — cliff calendar, originator estates, attackable patents
- Infantile autism treatment landscape brief
- Infantile autism treatment updates RSS
Frequently asked questions about Infantile autism
What drugs treat Infantile autism?
Tracked treatments include Abilify, Risperdal.
What is the treatment for Infantile autism?
Standard treatment for Infantile autism includes Abilify, Risperdal. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Infantile autism patent cliff · Infantile autism CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Risperdal · Johnson & Johnson (Janssen)
- Treatment: Abilify · Generic (originally Otsuka/BMS)
- Treatment: Risperdal · Ohio State University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing